Exact Sciences Q1 2024 GAAP EPS $(0.60) Misses $(0.48) Estimate, Sales $638.000M Beat $627.365M Estimate
Exact Sciences Q1 2024 GAAP EPS $(0.60) Misses $(0.48) Estimate, Sales $638.000M Beat $627.365M Estimate
Exact Sciences 2024年第一季度GAAP每股收益美元（0.60）未達到預期（0.48），銷售額6.38億美元超過6.27365億美元的預期
Exact Sciences (NASDAQ:EXAS) reported quarterly losses of $(0.60) per share which missed the analyst consensus estimate of $(0.48) by 25 percent. The company reported quarterly sales of $638.000 million which beat the analyst consensus estimate of $627.365 million by 1.70 percent. This is a 5.90 percent increase over sales of $602.450 million the same period last year.
Exact Sciences（納斯達克股票代碼：EXAS）公佈的季度虧損爲每股0.60美元，比分析師普遍預期的0.48美元（0.48美元）低25％。該公司公佈的季度銷售額爲6.38億美元，比分析師普遍預期的6.27365億美元高出1.70％。這比去年同期的6.0245億美元銷售額增長了5.90％。